One place for your practice and patients, every step of the way

Personalized education and customized treatment support through a single point of engagement

Prescribe and connect your patients to myAgios® Patient Support Services

Prescribe online

Having trouble? Download the form instead.

You can also get started by calling us at 1-877-77-AGIOS (1-877-772-4467),
 Mon-Fri, 8 AM to 8 PM ET.

Starting PYRUKYND

All-in-one enrollment and support for your patients

myAgios offers centralized support for your office staff when seeking care for your patients living with pyruvate kinase (PK) deficiency.

Personalized Patient Education

At diagnosis or when the patient wants to learn more, the Agios Clinical Educator (ACE) provides education and support.

Prescription Support
and Program
Enrollment

To prescribe PYRUKYND, you complete the PYRUKYND Start Form and your office submits it to myAgios.

Prescribe online

Access and Assistance

Patient Support Managers (PSMs) work directly with your patients and your practice to discuss PYRUKYND and how to access it, and coordinate delivery through the exclusive specialty pharmacy.

Customized Treatment
Support and
Adherence

Patients can get help to prepare for appointments and get questions about PYRUKYND answered via text or call with their ACEs or PSMs.

Your patients have a dedicated team at myAgios

Agios Clinical Educators (ACEs) and Patient Support Managers (PSMs) are here to help guide your patients living with PK deficiency along every step of their journey.

What's an ACE?

An Agios Clinical Educator (ACE) is there from the start to offer personalized guidance to people living with PK deficiency, with or without a prescription.*

ACEs help your patients:

Get introduced to the PSM to learn more about their health insurance options

Learn about their disease, set goals for living with their condition, and discuss treatment considerations

Connect with other patients and hear from experts with webinars

Find an ACE for your patients

What's a PSM?

A Patient Support Manager (PSM) guides patients in helping get their prescription filled, qualify for financial assistance, get personalized support, and more.*

PSMs help your patients:

  • Connect to ACEs to learn about their condition and treatment considerations
  • Understand financial assistance options and eligibility criteria
  • Obtain resources and encouragement through phone calls, emails, and SMS (text messages), starting at treatment initiation

PSMs help you and your office:

  • Navigate the patient's insurance coverage
  • Address prior authorization requirements and appeals
  • Coordinate all fulfillment and delivery with the exclusive specialty pharmacy
Find your PSM

*ACEs and PSMs do not provide medical advice. For medical advice or treatment-related questions, patients are instructed to talk to their healthcare team.

The myAgios team can connect with your patients both in English and in Spanish.

Financial support for your patients

myAgios can connect patients to financial assistance and coverage support programs to help with access to PYRUKYND.

Here are 3 ways our myAgios team helps your patients get, afford, and continue on PYRUKYND

$0 responsibility for commercially insured patients, regardless of how much they make

This program lowers costs for eligible patients to $0 per prescription, if their prescription copay exceeds that amount. Support is available for those who qualify. Patients who have government insurance are not eligible for this program.

Please see full Terms and Conditions for more information.

We’re ready to help!

If you and your practice have any questions about patient eligibility, find your PSM for answers or call us at 1-877-77-AGIOS (1-877-772-4467).

Find your PSM

Prescribe and connect your patients

The PYRUKYND Start Form connects your patients to all the support they need—all in one place.

Prescribe online

Explore more

Find out more about efficacy, safety, and dosing for PYRUKYND.

Visit PYRUKYND.com/HCP

We’re ready to help

If you and your practice have any questions about patient eligibility, find your PSM for answers.

Find your PSM

Or call us at 1-877-77-AGIOS (1-877-772-4467).

INDICATION
IMPORTANT SAFETY INFORMATION

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Hepatocellular Injury in Another Condition: In patients with another condition treated with mitapivat at a higher dose than that recommended for patients with PK deficiency, liver injury has been observed. These events were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of >5× upper limit of normal (ULN) with or without jaundice. All patients discontinued treatment with mitapivat, and these events improved upon treatment discontinuation.

Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is >5× ULN. Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected.

Adverse Reactions: The most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.

  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.

  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.

  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.

  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

INDICATION

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Please see full Prescribing Information for PYRUKYND.